7 completed. 7 Phase 1.
By phase and status
Follow tebipenem: new trials by email Literature Review of tebipenem trials Research Report on tebipenem
Trials (filtered) newest first · largest first
All 7 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants TBP-PI-HBr - Healthy Participants | Phase 1 | Completed | 39 | 2024-11-20 | 2025-05-20 |
A Study to Compare Two Bioanalytical Assays for Tebipenem TBP-PI-HBr - Healthy Volunteers | Phase 1 | Completed | 20 | 2023-05-04 | 2024-03-27 |
Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers TBPM-PI-HBr - Healthy Volunteers | Phase 1 | Completed | 30 | 2020-12-07 | 2021-03-16 |
Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL), Omeprazole - Healthy Volunteers | Phase 1 | Completed | 20 | 2020-07-01 | 2020-09-04 |
A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Moxifloxacin 400mg, Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) - TQT Study | Phase 1 | Completed | 24 | 2020-01-19 | 2020-03-13 |
Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Renal Impairment | Phase 1 | Completed | 39 | 2019-12-06 | 2020-11-27 |
Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 SPR994, Placebo Oral Tablet, Orapenem® - Healthy Volunteers | Phase 1 | Completed | 124 | 2017-10-20 | 2018-08-28 |
Conditions studied
Kidney Diseases (1) · Renal Insufficiency (1)
Sponsors
Spero Therapeutics (7)
Countries
United States (6) · Australia (1)
Top investigators
David Melnick, M.D. (2) · Charlotte Lemech, FRACP, MD (1) · David Baratz, MD (1)
Results publications
PMID 31262768, PMID 35420493, PMID 35762796